BACKGROUND: NK cells are characterized by cytotoxic activity against tumor cells and CD3-CD16+CD56+ phenotype. Two distinct subpopulations of NK cells were characterized in the peripheral blood: NK-CD56 dim representing over 95% of NK cells and involved in antitumor cytotoxicity, and NK-CD56
Introduction
NK cells are characterized as large granular lymphocytes with the CD3 -CD16 + CD56 + phenotype [1] [2] [3] and antitumor cytotoxic activity [4] [5] [6] [7] . Other molecules associated with these cells have been described, such as adhesion molecule CD57, cytotoxicity receptors KIR (CD158), LIR (CD85), NKG2 (CD94, CD315) and NKP (CD335, CD336) [8] [9] [10] [11] . During the last decade, two distinct subpopulations of NK cells were characterized as having primary phenotypic expression associated with a specific function: NK-CD56 dim (CD56 dim/neg , CD56 low ) and NK-CD56 bright (CD56 high ) [12] [13] [14] . NK-CD56 dim cells comprise the majority of peripheral blood and spleen NK cells (> 95%), they have CD16 +/-CD57 -KIR + NKP + phenotype and are involved in antitumor cytotoxicity [15, 16] . NK-CD56 bright cells represent approximately 10% of all NK cells, are mainly located in the lymph nodes and tonsils, express predominantly CD16 +/-CD57 -KIR -phenotype, lacking cytotoxicity receptors but are involved in the active secretion of cytokines [17] [18] [19] .
The particular distribution of NK subpopulations can be significant and suggestive when evaluating their cytotoxic potency as vigorous antitumor cellular immune response players. Some deficiencies in the function of tumor-infiltrating NK cells have been observed [20] [21] [22] [23] . This phenomenon seems to be facilitated by chemokines [24] and upon IL-2, IL-12 or IL-15 stimulation [25] . Although some particular aspects of NK subpopulations distribution in the peripheral blood have been already observed in viral diseases [26, 27] , pregnancy [28, 29] and even in autoimmune diseases [30] , data regarding their value in the diagnosis of cancer are scarce.
Based on our preliminary studies [31] , we now attempt to compare different aspects of the phenotype and peripheral NK cell subpopulations along the three progressive stages of tumor development: primary tumor (PT), lymph node invasion (LNI), metastases (Mt). We consider that, among other features, the diagnosis and monitoring of tumor development depend on the assessment of changes in the distribution of NK cells.
Materials and Methods

Patients
Whole peripheral blood samples were collected from 36 cancer patients (24 patients with PT, 6 patients with LNI and 6 patients with Mt). All subjects gave informed consent before their inclusion in the study.
PTs were 10 retroperitoneal, 2 kidney, 2 bladder, 4 colons, 2 gastric, 2 breasts, 1 ovarian, 1 pelvis. There were 11 man and 13 women, average age 62. The patients with LNI had either osteosarcoma, breast, squama cellular, colon, renal and perineal tumor. There were 4 man and 2 women, average age 63. Mt came from 3 colorectal, 1 gastric, 1 breast and 1 retroperitoneal carcinoma. There were 4 man and 2 women, average age 65.
No patient supported immunomodulatory treatment at the moment of testing. Blood samples from 10 healthy donors served as controls.
The study was approved by the institution ethics committee.
Lymphocyte immunophenotyping
All patients and control subjects were tested for lymphocyte populations (T, B and NK cells) by flow cytometry immunophenotyping at FACSCalibur cytometer (BD Biosciences, San Jose, CA, USA), using 4-colour automatic methodology. The blood was processed with MultiTest IMK Kit (BD Biosciences) according to manufacturer's instructions. Data acquisition was performed using BD MultiSet software.
Characterization of NK cells
Given that MultiTest immunophenotyping kit evaluates only CD16
+ NK cells subset, we performed an additional analysis of NK cell phenotype by assessing CD16/CD57 expression and CD56 dim /CD56 bright subpopulations. The analysis was performed in 8 patients with PT and all patients with LNI and Mt. The peripheral blood samples were labeled with CD3PerCP, CD56APC, CD16PE and CD57FITC (BD Biosciences) and then phenotyped at FACSCalibur cytometer by the 4-color manual method, using BD CellQuest software for data acquisition ( Figure 1 ). All monoclonal antibodies were used according to manufacturer's instructions as previously described [32] . 
Statistical analysis
The results are presented as the mean ± standard deviation of cell percentages.
The T, B and NK cells were measured as a percentage of total lymphocytes. Normal ranges are 5 th to 95 th percentile, as stated in Table 1 .
NK subpopulations and cell phenotypes were calculated as percentages of total CD56 + cells.
Results
Lymphocyte immunophenotyping
The populations of peripheral blood lymphocytes revealed some differences in the distribution of cells between the three stages of tumor development (Table I) . Thus, CD4
+ T-cells and B cells were higher in patients with PTs compared to the level observed in patients with Mt. CD8 + T cells were higher in patients with Mt, compared to the patients with PT. In addition, T-CD4+: T-CD8+ ratio was lower in LNI and Mt patients than in patients with PTs. The distribution of NK cells did not show any significant variation between control subjects and patients with PTs. Also, no significant imbalance has been observed during the stages of tumor development in terms of percentage of NK cells. Table 2 .
Characterization of NK cells a. CD16/CD57 expression
Irrespective of CD16
+ or CD57 + phenotype, the percentages of single-or double-positive cells were the lowest in patients with LNI as compared to controls or PT and Mt patients. As considering the three tumor development stages, the percentages of single-or double-positive cells were significantly higher in patients with PT, with no significant difference when comparing to controls. It must be emphasized that the values are not statistically significant because the three groups did not include the same patients. However, they could highlight a possible trend in expression of CD16/CD57 markers along the evolutionary phases of the tumor. http://www.id-press.eu/seejim/
Discussion
We have focused on assessing the NK cell population in terms of its representation during the progressive stages of malignancy, from primary tumors, lymph nodes involvement to distant sites metastasis (PT, LNI, Mt). It is known that NK cells are actively involved in the anti-tumoral response, hence, we wanted to evaluate NK cell phenotype and their subpopulations distribution in the peripheral blood as possible indicators of tumor development to more advanced stages. At the same time, evaluating the specific phenotype in relation to tumor evolution, new markers indicating antitumor cellular cytotoxicity could be revealed. We have purposely chosen different solid cancers to highlight that stages of tumor development can have common immune-related mechanisms, possibly sustained by a clear anti-tumoral cell like NK population.
The above-mentioned stages of tumor progression we considered were mainly clinical, concerning that they were diagnosed by standard clinical/paraclinical methods. Therefore, an auxiliary method as the determination of NK cells supplies additional information, indicating how the tumor growth and evolution affect these cells. This could be important since the non-surgical anti-tumor therapy may target for specific NK activity improvement [22] .
The percentages of peripheral blood NK cells varied slightly in patients at different stages of tumor development. In spite of this minor variation, other data can be provided by analyzing the expression of CD16 and CD57 molecules or distribution of NK-CD56 dim / NK-CD56 bright subsets. Although functional differences between the two NK subpopulations are well known [15, 17] , relatively little evidence was provided about their participation in specific antitumor response and their possible assessment during tumor development.
We also have observed two changes in NK subpopulațions during tumor evolution: a downward trend in the share of NK-CD56 dim subpopulation and on the other hand a progressive increase of NK-CD56 bright subpopulation. Taking into account that NK-CD56 dim cells exert largely cytotoxic actions, we assume that tumor progression could be favored by the decrease of this subpopulation. Given that the increased NK-CD56 bright cells develop regulatory activities, it can be concluded that they are not very effective in the recruitment of other active cytotoxic cells, such as CD8 + T cells, which are essential to the eradication of metastatic tumors [33] . Even if we found significantly increased peripheral blood CD8 + T cells in patients with Mt compared to PT patients, it is doubtful whether these cytotoxic cells are capable of working effectively. For this reason, we tend to assume that changing the NK-CD56 dim /NK-CD56 bright balance in favor of NK-CD56 bright cells may represent probably a warning sign for tumor escape.
Examining the CD16/CD57 phenotype, we observed that the percentages of positive NK cells were significantly lower in patients with LNI compared to the levels observed in PT or Mt patients. Knowing that both CD16 and CD57 molecules are involved in intercellular interactions, we can emphasize that this decrease could be an issue in NK cell adhesion during tumor growth, especially in the lymph node invasion process, which seems to be a critical moment. This phenomenon may be exacerbated by the lower NK-CD56 dim subpopulation with decreased CD16/CD57 expression and cannot be corrected by the increase of NK-CD56 bright subset. Thus, such a hypothetical replacement of a cytotoxic subpopulation (NK-CD56 dim ) with a regulatory subpopulation (NK-CD56 bright ) cannot be beneficial in terms of cytotoxicity efficiency and anti-tumoral effect [5] .
Our presented results pinpoint an ineffective change of the peripheral blood NK cells during tumorigenesis and tumor dynamics: gradual decrease of the NK-CD56 dim and increase of the NK-CD56 bright subpopulations. This could favor tumor invasion in the lymph nodes, ending with a reversal of the NK-CD56 dim / NK-CD56 bright distribution in the course of metastasis process. Changing in CD16/CD57 coexpression on NK cells can cause difficulties in efficient cytotoxicity by reducing the intercellular contact, a critical step in developing an anti-tumoral effect. Each of these changes contributes to the ineffectiveness of NK cells and hence tumor progression. These features can be sensed indirectly by phenotypic characterization of NK cells and their subpopulations and could be cellular markers of poor clinical outcome in solid tumors.
